{"product_id":"servier-swot-analysis","title":"Servier SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eServier’s strengths in R\u0026amp;D and global generics position it well against regulatory and pricing pressures, but patent cliffs and emerging-market competition pose clear risks; our full SWOT unpacks these dynamics with actionable recommendations for investors and strategists. Purchase the complete analysis to receive a professionally formatted, editable Word report and Excel matrix—ideal for planning, pitching, and confident decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnique Foundation Led Governance Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier is governed by the Servier International Foundation, a non-profit that shields management from short-term market and activist pressure, enabling multi-year R\u0026amp;D plans; the group reported R\u0026amp;D investment of €1.2bn in 2024, about 22% of revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Strategic Pivot to Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier pivoted to oncology, turning it into a core pillar via acquisitions and internal R\u0026amp;D; the 2023 buy of Agios Pharmaceuticals’ oncology unit plus launch of IDH inhibitors (including 2024 EU\/US launches) pushed oncology sales to an estimated €850m in 2025, shifting revenue mix from primary care toward higher-margin specialty drugs and reducing reliance on generics and cardiovascular franchises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Reinvestment Rate in Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier consistently invests over 20% of annual revenue in R\u0026amp;D—about €1.1bn in 2024 versus an industry average near 15%—supporting a pipeline of 45+ clinical candidates and ensuring steady entry of new assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Commercial Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eServier operates in over 150 countries, giving it a wide commercial network that reduced regional revenue volatility; in 2024 group sales were €4.9bn, with \u0026gt;40% from emerging markets, helping absorb downturns in Europe.\u003c\/p\u003e\n\u003cp\u003eThe company’s established country affiliates and 25+ local manufacturing sites speed regulatory launches—Servier achieved 12 new market approvals in 2024—supporting fast therapy rollouts across diverse regimes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePresence: \u0026gt;150 countries\u003c\/li\u003e\n\u003cli\u003e2024 sales: €4.9bn\u003c\/li\u003e\n\u003cli\u003eEmerging market share: \u0026gt;40%\u003c\/li\u003e\n\u003cli\u003eLocal sites: 25+ factories\u003c\/li\u003e\n\u003cli\u003e2024 approvals: 12 markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in Cardiovascular and Metabolic Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eServier’s long heritage in cardiovascular and metabolic care drives steady revenue: in 2024 its cardiometabolic portfolio generated ~€1.1bn, supplying predictable cash flow and high HCP recognition across 120+ countries.\u003c\/p\u003e\n\u003cp\u003eThat financial base funds R\u0026amp;D and expansion into specialty areas, lowering risk when investing in oncology and rare-disease programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 cardiometabolic revenue ~€1.1bn\u003c\/li\u003e\n\u003cli\u003ePresence in 120+ countries\u003c\/li\u003e\n\u003cli\u003eStable, high-recognition brands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier doubles down on oncology: €1.2bn R\u0026amp;D, €4.9bn sales and €850m oncology push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier’s foundation ownership enables multi-year R\u0026amp;D with €1.2bn invested in 2024 (~22% of revenue), supporting a 45+ candidate pipeline and specialty shift; oncology now a core pillar after Agios unit buy, driving estimated €850m oncology sales in 2025. Global reach (150+ countries, \u0026gt;40% sales from emerging markets) and 25+ manufacturing sites delivered €4.9bn sales and 12 approvals in 2024, while cardiometabolic products still produced ~€1.1bn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales\u003c\/td\u003e\n\u003ctd\u003e€4.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€1.2bn (22% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology sales\u003c\/td\u003e\n\u003ctd\u003e€850m (est 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiometabolic\u003c\/td\u003e\n\u003ctd\u003e€1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e150+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging mkts\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e25+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew approvals\u003c\/td\u003e\n\u003ctd\u003e12 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Servier, highlighting its core strengths and weaknesses, identifying strategic opportunities for growth and innovation, and outlining external threats and market risks shaping the company’s competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix tailored to Servier for rapid alignment of R\u0026amp;D, commercial and regulatory strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Mature Product Portfolios\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant share of servier revenue still comes from legacy drugs nearing or past patent expiry sales according to company filings exposes the firm rapid price erosion as generics enter for example market similar portfolios fell within months post-loss exclusivity in peer cases. transitioning specialty spend rose is vital but will take years and carries execution risk.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Scale Compared to Global Mega Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite global operations, Servier’s 2024 revenue of about €4.8bn lags mega-pharma peers (Pfizer €58bn, Roche €60bn), limiting ability to fund multi-billion acquisitions and reducing bargaining power in licensing auctions.\u003c\/p\u003e\n\u003cp\u003eThis scale gap constrains bids for high-value late-stage assets, where deals often exceed €5–10bn, forcing Servier to lose out to larger acquirers.\u003c\/p\u003e\n\u003cp\u003eServier must therefore be highly selective and drive capital efficiency—prioritizing deals with clear ROI and partnering to share risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Legal and Reputational Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier faced major legal and reputational hits from past product litigations in Europe, notably the Mediator (benfluorex) case that led to over €1.3 billion in provisions and settlements by 2020 and ongoing legacy costs into 2024.\u003c\/p\u003e\n\u003cp\u003eThese outcomes forced multi-year compliance overhauls and public trust-rebuilding campaigns; maintaining a spotless compliance record is critical to prevent further brand devaluation and avoid new financial hits that could exceed hundreds of millions annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderrepresentation in the United States Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eServier has grown its US presence but still trails big pharma: as of 2024 its US market share remained under 1% versus leaders holding double‑digit shares, limiting reach for oncology launches in the world’s largest market (US Rx spending $582B in 2024, IQVIA). \u003c\/p\u003e\n\u003cp\u003eScaling in the US needs heavy capex—commercial teams, distribution, trials—plus payer navigation; US launch costs often exceed $200M‑$500M per oncology asset, raising execution risk for Servier’s pipeline. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS Rx market $582B (2024)\u003c\/li\u003e\n\u003cli\u003eServier US share \u0026lt;1% (2024)\u003c\/li\u003e\n\u003cli\u003eTypical US oncology launch cost $200M‑$500M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Complexity in Organizational Transition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShifting Servier from primary care to specialty and oncology raises internal friction and higher operational complexity, risking sales continuity as 2024 oncology revenue aimed to hit ~25% of group sales vs 15% in 2020.\u003c\/p\u003e\n\u003cp\u003eRetraining thousands of reps and changing culture for precision medicine (genomics, biomarkers) demands multiyear investment; HR and training costs could exceed €50–100m, straining margins.\u003c\/p\u003e\n\u003cp\u003eMaintaining current performance while executing transformation may reduce efficiency—productivity dips and longer launch timelines could cut EBITDA by 1–3% during transition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue mix shift: 15%→25% (2020→2024 target)\u003c\/li\u003e\n\u003cli\u003eEstimated retraining cost: €50–100m\u003c\/li\u003e\n\u003cli\u003eEBITDA drag risk: 1–3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier risk profile: legacy reliance, tiny US foothold, costly oncology pivot threatens EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpservier weaknesses: heavy reliance on legacy drugs of sales scale gap revenue vs peers us share rx and high oncology launch costs lingering mediator liabilities\u003e€1.3bn provisions historically), costly retraining (€50–100M) and potential EBITDA drag 1–3% during shift to specialty.\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy drug share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e€4.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS market share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Rx market\u003c\/td\u003e\n\u003ctd\u003e$582B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology launch cost\u003c\/td\u003e\n\u003ctd\u003e€200–500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetraining cost\u003c\/td\u003e\n\u003ctd\u003e€50–100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEBITDA drag risk\u003c\/td\u003e\n\u003ctd\u003e1–3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistoric provisions (Mediator)\u003c\/td\u003e\n\u003ctd\u003e€1.3bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pservier\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eServier SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is a real excerpt from the complete Servier SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality and ready-to-use insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752688365945,"sku":"servier-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/servier-swot-analysis.png?v=1772243871","url":"https:\/\/matrixbcg.com\/products\/servier-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}